Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
LENZ Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
146 institutional managers report a position in LENZ Therapeutics, Inc. worth $199.2M between them, filed on form 13F for the quarter ending 2026-06-30. 19 of them hold 80% of it, the largest being RA Capital Management, LLC at 11.92%.
121 more managers in the register
19 managers hold 80% of the $199.2M institutional base. The other 127 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
LENZ (LENZ Therapeutics, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
via RA Capital Management, LLC, Versant Venture Management, LLC, Rock Springs Capital Management LP +2 more · 11.92% of LENZ, 11.22% of IPSC
via RA Capital Management, LLC, Standard Life Aberdeen plc, Trexquant Investment LP +1 more · 11.92% of LENZ, 11.94% of SPRY
via RA Capital Management, LLC, Alyeska Investment Group, L.P., Qube Research & Technologies Ltd +4 more · 11.92% of LENZ, 18.27% of JANX
via RA Capital Management, LLC, Marshall Wace LLP, Trexquant Investment LP +2 more · 11.92% of LENZ, 15.13% of ACET
via RA Capital Management, LLC, CAM Group Holding A/S, Rock Springs Capital Management LP +3 more · 11.92% of LENZ, 13.22% of ZLAB
via RA Capital Management, LLC, Blue Owl Capital Holdings LP, Alyeska Investment Group, L.P. · 11.92% of LENZ, 44.47% of ARTV
Managers holding a meaningful stake in LENZ also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.